Methotrexate polyglutamates as a marker of patient compliance and clinical response in psoriasis: A single-centre prospective study

British Journal of Dermatology

Volumn 167, Issue 1, 2012, Pages 165-173

  Woolf, R T ^a   West, S L ^a   Arenas Hernandez, M ^b   Hare, N ^a   Peters Van Ton, A M ^a   Lewis, C M ^a   Marinaki, A M ^b   Barker, J N W N ^a   Smith, Catherine H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; METHOTREXATE POLYGLUTAMATE;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIASIS SEVERITY INDEX; SIDE EFFECT; STEADY STATE; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; BIOLOGICAL MARKERS; CHRONIC DISEASE; DERMATOLOGIC AGENTS; ERYTHROCYTES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; METHOTREXATE; MIDDLE AGED; POLYGLUTAMIC ACID; PROSPECTIVE STUDIES; PSORIASIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863332183     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10881.x     Document Type: Article

References (36)

1. Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2):1-70.
2. Menter A, Korman NJ, Elmets SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61:451-85.
3. Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158:558-66. (Pubitemid 351239154)
4. Heydendael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349:658-65. (Pubitemid 36975998)
5. Haustein UF, Rytter M. Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol 2000; 14:382-8. (Pubitemid 32898892)
6. Finlay AY, Smith CH. General aspects of therapy. In: Rook's Textbook of Dermatology (Burns T, Breathnach S, Cox N, Griffiths C, eds), 8th edn. London: Wiley-Blackwell, 2010; 72.1-33.
7. Becker ML, van Haandel L, Gaedigk R et al. Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations. Arthritis Rheum 2010; 62:1803-12.
8. Dervieux T, Orentas Lein D, Marcelletti J et al. HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem 2003; 49:1632-41. (Pubitemid 37194217)
9. Chládek J, Grim J, Martínková J et al. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol 2002; 54:147-56. (Pubitemid 35024938)
10. Allegra CJ, Chabner BA, Drake JC et al. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985; 260:9720-6. (Pubitemid 15013030)
11. Cronstein BN, Naime D, Ostad E. The anti-inflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92:2675-82. (Pubitemid 24006532)
12. Montesinos MC, Desai A, Delano D et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003; 48:240-7. (Pubitemid 36091669)
13. Cronstein B. How does methotrexate suppress inflammation? Clin Exp Rheumatol 2010; 28 (Suppl. 61):S21-3.
14. Peng Z, Fernandez P, Wilder T et al. Ecto-5′-nucleotidase (CD73)-mediated extracellular adenosine production plays a critical role in hepatic fibrosis. FASEB J 2008; 22:2263-72. (Pubitemid 351948645)
15. Peng Z, Borea PA, Varani K et al. Adenosine signalling contributes to ethanol-induced fatty liver in mice. J Clin Invest 2009; 119:582-94.
16. Chabner BA, Allegra CJ, Curt GA et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 1986; 76:907-12.
17. Dalrymple JM, Stamp LK, O'Donnell JL et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58:3299-308.
18. Schrøder H, Fogh K. Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 1988; 21:145-9. (Pubitemid 18087030)
19. Angelis-Stoforidis P, Vajda FJ, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol 1999; 17:313-20. (Pubitemid 29265678)
20. Dervieux T, Furst D, Lein DO et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004; 50:2766-74. (Pubitemid 39209513)
21. Dervieux T, Furst D, Lein DO et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 2005; 64:1180-5. (Pubitemid 41113353)
22. Stamp LK, O'Donnell JL, Chapman PT et al. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum 2010; 62:359-68.
23. National Institutes of Health and National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, 2010. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8. 5x11.pdf (last accessed 5 March 2012).
24. Chládek J, Simková M, Vanecková J et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 2008; 64:347-55.
25. Dervieux T, Zablocki R, Kremer J. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology 2010; 49:2337-45.
26. National Collaborating Centre for Primary Care, Royal College of General Practitioners. Medicines Adherence: Involving patients in decisions about prescribed medicines and supporting adherence. London: National Institute for Health and Clinical Excellence, 2009. Available at: http://www.nice.org.uk/ nicemedia/live/11766/42971/42971.pdf (last accessed 5 March 2012).
27. Stamp LK, O'Donnell JL, Chapman PT et al. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis Rheum 2009; 60:2248-56.
28. Woolf RT, Smith CH. How genetic variation affects patient response and outcome to therapy for psoriasis. Expert Rev Clin Immunol 2010; 6:957-66.
29. Campalani E, Arenas M, Marinaki AM et al. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol 2007; 127:1860-7. (Pubitemid 47075365)
30. Warren RB, Smith RL, Campalani E et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 2008; 128:1925-9. (Pubitemid 352001201)
31. Warren RB, Smith RL, Campalani E et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol 2009; 160:438-41.
32. Dervieux T, Kremer J, Lein DO et al. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamyl hydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 2004; 14:733-9. (Pubitemid 39552788)
33. Stamp LK, Chapman PT, O'Donnell JL et al. Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenet Genomics 2010; 20:367-76.
34. Becker ML, Gaedigk R, van Haandel L et al. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum 2011; 63:276-85.
35. Brooks AJ, Begg EJ, Zhang M et al. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther Drug Monit 2007; 29:619-25. (Pubitemid 47494061)
36. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005; 64 (Suppl. 2):S65-8.